Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

4CSS

Crystal structure of FimH in complex with a sulfonamide biphenyl alpha D-mannoside

Summary for 4CSS
Entry DOI10.2210/pdb4css/pdb
Related4CST 4CSY
DescriptorPROTEIN FIMH, 4'-(alpha-D-Mannopyranosyloxy)-biphenyl-4-methyl sulfonamide, GLYCEROL, ... (4 entities in total)
Functional Keywordssugar binding protein, fimh antagonists, type i pili, uti, upec, adhesin
Biological sourceESCHERICHIA COLI K-12
Cellular locationFimbrium : P08191
Total number of polymer chains1
Total formula weight17958.03
Authors
Primary citationKleeb, S.,Pang, L.,Mayer, K.,Eris, D.,Sigl, A.,Preston, R.C.,Zihlmann, P.,Sharpe, T.,Jakob, R.P.,Abgottspon, D.,Hutter, A.S.,Scharenberg, M.,Jiang, X.,Navarra, G.,Rabbani, S.,Smiesko, M.,Ludin, N.,Bezencon, J.,Schwardt, O.,Maier, T.,Ernst, B.
Fimh Antagonists: Bioisosteres to Improve the in Vitro and in Vivo Pk/Pd Profile.
J.Med.Chem., 58:2221-, 2015
Cited by
PubMed Abstract: Urinary tract infections (UTIs), predominantly caused by uropathogenic Escherichia coli (UPEC), belong to the most prevalent infectious diseases worldwide. The attachment of UPEC to host cells is mediated by FimH, a mannose-binding adhesin at the tip of bacterial type 1 pili. To date, UTIs are mainly treated with antibiotics, leading to the ubiquitous problem of increasing resistance against most of the currently available antimicrobials. Therefore, new treatment strategies are urgently needed. Here, we describe the development of an orally available FimH antagonist. Starting from the carboxylate substituted biphenyl α-d-mannoside 9, affinity and the relevant pharmacokinetic parameters (solubility, permeability, renal excretion) were substantially improved by a bioisosteric approach. With 3'-chloro-4'-(α-d-mannopyranosyloxy)biphenyl-4-carbonitrile (10j) a FimH antagonist with an optimal in vitro PK/PD profile was identified. Orally applied, 10j was effective in a mouse model of UTI by reducing the bacterial load in the bladder by about 1000-fold.
PubMed: 25666045
DOI: 10.1021/JM501524Q
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (1.069 Å)
Structure validation

238268

数据于2025-07-02公开中

PDB statisticsPDBj update infoContact PDBjnumon